A recent review in Nature Communications highlights the crucial role of innovative startups in advancing alternative protein sources to tackle global food security challenges and translate these efforts into commercial applications.
SkinTE by RegenETP for Diabetic Foot Ulcers: Likelihood of Approval
SkinTE is under clinical development by RegenETP and currently in Phase III for Diabetic Foot Ulcers.